CUL Stock Overview
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Aspira Women's Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$4.50 |
| 52 Week Low | US$0.17 |
| Beta | 1.37 |
| 1 Month Change | -58.64% |
| 3 Month Change | -71.22% |
| 1 Year Change | -95.96% |
| 3 Year Change | -98.71% |
| 5 Year Change | -98.53% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -37.2% | 1.4% | 2.7% |
| 1Y | -96.0% | -2.8% | 17.0% |
Return vs Industry: CUL underperformed the German Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: CUL underperformed the German Market which returned 17% over the past year.
Price Volatility
| CUL volatility | |
|---|---|
| CUL Average Weekly Movement | 19.5% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CUL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CUL's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 64 | Mike Buhle | aspirawh.com |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Aspira Women's Health Inc. Fundamentals Summary
| CUL fundamental statistics | |
|---|---|
| Market cap | €3.75m |
| Earnings (TTM) | -€14.10m |
| Revenue (TTM) | €8.54m |
0.4x
P/S Ratio-0.3x
P/E RatioIs CUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUL income statement (TTM) | |
|---|---|
| Revenue | US$8.96m |
| Cost of Revenue | US$3.75m |
| Gross Profit | US$5.21m |
| Other Expenses | US$20.00m |
| Earnings | -US$14.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 58.12% |
| Net Profit Margin | -165.07% |
| Debt/Equity Ratio | -62.0% |
How did CUL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 22:02 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aspira Women's Health Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Laura McGuigan | B. Riley Securities, Inc. |